|
|
|
|
|
|
Article Detail
|
|
Label
|
|
|
Label
|
|
|
|
The anti -Parkinson effects of Liraglutide in rat model of Rotenone induced Parkinsonism
|
|
| Author:
|
SHEREEN M. MEKKEY, AHMED RAHMAH ABU RAGHIF, HAIDER ABDUL RIDHA ALKAFAJI, NAJAH R. HADI
|
| Abstract:
|
Using the classical dopamine-based anti-Parkinson drugs is associated with a broad spectrum of dilemmas that created the urgent need to include drugs that targets the other pathological events that accompanies the neuro degeneration process such as: oxidative stress, inflammation apoptosis, and formation of a-syncline aggregates, the various advantageous effects of Liraglutide lead to expect further neuroprotective effects. This study aims to investigate the anti-inflammatory, anti-oxidant, and anti-apoptotic effects of Liraglutide by measurement of dopamine (DA), tyrosine hydroxylase (TH), IL-1ß, IL-6, cytochrome-c (Cyt-c), caspase-3 (Cas-3), myeloperoxidase (MPO), and a-syncline(SNCA) expression in midbrain samples of animal model of rotenone induced Parkinson disease (PD), and to perform neurobehavioral analysis and to compare it to that of pramipexole. 40 male albino rats were equally divided into: healthy control (no treatment), induction group (rotenone induced PD, 2.5 mg/kg IP every 48 hr for 20 days), pramipexole group (as in induction + pramipexole 1mg/kg orally after 30 min), Liraglutide group (as in induction+liraglutide50 µcg/kg Scafter 30 min).Compared to the induction group Liraglutide could significantly increase locomotion duration, reduce the duration to cross the balance beam, reduce the cataleptic state (p<0.01), it could also significantly increase DA content of midbrain tissue samples, and significantly reduceIL-1ß, cas-3, Cyt–c, SNCA (p<0.01). Compared to pramipexole, Liraglutide could significantly increase open field locomotion duration, the duration to cross the balance beam and number of slips, and significantly reduce the duration to slip down the vertical pole (p<0.01), it revealed a significantly higher IL-1ß tissue content, and SNCA expression (p<0.01). It was concluded that Liraglutide has potential anti-Parkinson effects that is worthy of further research.
|
| Keyword:
|
Liraglutide, Parkinson disease (PD).
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.SP2.449
|
| Download:
|
Request For Article
|
|
|
|
|
|
|
|
|
|
|